NovaBay Pharmaceuticals Inc New (NBY) News

Form D - Notice of Exempt Offering of Securities

Form 8-K - Current report

Form 8-K - Current report

NovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic Membranes

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces its partnership with Woo University to support the education of eyecare...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

NovaBay Pharmaceuticals Reports Third Quarter 2023 Financial Results

Net product revenue from Avenova®-branded eyecare products grew 7% year-over-year, reflecting an increased contribution from the physician...

NovaBay Pharmaceuticals to Hold Third Quarter 2023 Conference Call on November 9, 2023

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and nine months ended September...

NovaBay Pharmaceuticals Expands Physician Dispensed Sales Channel with New Avenova Programs

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care...

NovaBay Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care...

Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference

JUPITER, Fla., Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Dawson James Securities, Inc...

NovaBay Pharmaceuticals Announces Commercial Launch of Avenova® Allograft

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces the commercial launch of Avenova Allograft to eyecare professionals across the U.S...

NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova® Allograft

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and BioStem Technologies, Inc. (OTC: BSEM) announce an agreement under which NovaBay has been...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

NovaBay Pharmaceuticals Reports Second Quarter 2023 Financial Results

Net product revenue of $4.6 million increased 26% over the prior-year quarter Wound care sales of $1.3 million mark a record quarterly high...

NovaBay Pharmaceuticals to Hold Second Quarter 2023 Conference Call on August 10, 2023

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and six months ended June 30...